Bridgebio Pharma Inc. disclosed positive top-line results from Propel 3, the global phase III pivotal study of oral infigratinib in children with achondroplasia. Change from baseline in annualized ...
Beginning Feb. 2, 2026, medical technology news and analysis will be integrated into BioWorld, where curated coverage will continue as part of BioWorld’s core reporting. This transition reflects how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results